WHO backs Cervarix for use in developing countries

GlaxoSmithKline has cleared a key hurdle for gaining wider use of its cervical cancer vaccine Cervarix, winning the World Health Organization's approval to offer the jab in developing countries. That official green light is a prerequisite for non-profit groups as well as UN agencies that want to buy the vaccine.

And Glaxo quickly followed up, saying that the company plans to explore new financing mechanisms that would ensure broad availability. "We're exploring a variety of distribution partnerships to ensure Cervarix will protect women and girls around the globe," Jean Stephenne, head of vaccines, tells Reuters.

WHO had already approved Gardasil and the Global Alliance for Vaccines and Immunization, a broad umbrella group of international health organizations, has made access to cervical cancer vaccines a top priority. "We're very eager to offer women in developing countries these vaccines because without early screening, they are arguably more vulnerable to cervical cancer," Dan Thomas, a GAVI spokesman, tells the AP.

It's likely that Glaxo will work out discount prices for global health agencies and nonprofits, a common avenue for Big Pharma companies selling expensive therapies in poor countries. But of the 280,000 women who die from cervical cancer each year, 80 percent live in the developing world. Broader access to lower cost vaccines would save many lives.

- read the report from Reuters
- read the story from the AP

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.